Alectinib-d8

• Description :

  Alectinib-d8 is the deuterium labeled Alectinib. Alectinib (CH5424802) is a potent, selective, and orally available ALK inhibitor with an IC50 of 1.9 nM and a Kd value of 2.4 nM (in an ATP-competitive manner), and also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively[1]. Alectinib demonstrates effective central nervous system (CNS) penetration[2].

• Product Name Alternative :

  CH5424802-d8; RO5424802-d8; AF802-d8

• UNSPSC :

  12352005

• Target :

  Anaplastic lymphoma kinase (ALK) ; Isotope-Labeled Compounds

• Type :

  Isotope-Labeled Compounds

• Related Pathways :

  Others; Protein Tyrosine Kinase/RTK

• Field of Research :

  Cancer

• Solubility :

  10 mM in DMSO

• Smiles :

  N#CC1=CC2=C(C3=C(N2)C(C)(C4=CC(N5CCC(CC5)N6C([2H])([2H])C([2H])([2H])OC([2H])([2H])C6([2H])[2H])=C(C=C4C3=O)CC)C)C=C1

• Molecular Formula :

  C30H26D8N4O2

• Molecular Weight :

  490.67

• References & Citations :

  [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Sakamoto H, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell. 2011, 19 (5), 679-690.|[3]Gadgeel S, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018 Nov 1;29 (11) :2214-2222.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Isotope-Labeled Compounds

• Clinical Information :

  No Development Reported

• CAS Number :

  [1256585-15-5]